top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
iScreen Shoter - 20261028172009135.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
Frame 1000008569.png
Frame 1000008568.png
4acc1a9d-ced8-4f58-a79e-cd2ac6fe752e.png
Liver Attenuation.png
Frame 1000008251.jpg
Lung LAI.jpg
lung HAI.jpg
ٍEpicardial Fat .png
coronaryArteryCalcification.png
Thoracic Aorta and Pulmonary Artery Sizing .png
iScreen Shoter - 20261028184534618.jpg
Cardiac Chambers Volumetry.png
iScreen Shoter - 20261028184548151.jpg
aortic.jpg

Comparison of Two Deep Learning Models and Their Combination for One-Year Lung Cancer Detection in Two Screening Cohorts

4 hours ago
2 min read

Submitted manuscript | Original research review

This study compares two complementary deep-learning approaches for detecting lung cancer within one year of baseline low-dose CT (LDCT) screening: Sybil, which analyzes the whole scan, and a MONAI-based model focused on pulmonary nodules. It also evaluates a prespecified composite model designed to combine their signals.

Study design

The retrospective analysis included 5,110 baseline LDCT examinations from two screening cohorts: the US National Lung Screening Trial (NLST; 2,343 examinations) and the Pamplona International Early Lung Cancer Action Program (P-IELCAP; 2,767 examinations). The composite OR-stacked model combined Sybil, the MONAI nodule model, and a safety-net rule for MONAI-detected nodules larger than 6 mm with confidence above 0.95. The outcome was histologically confirmed lung cancer within one year.

Key findings

Sixty-five lung cancers were diagnosed within one year. Sybil showed an AUC of 0.93 in each cohort; the MONAI-based model achieved AUCs of 0.90 in NLST and 0.79 in P-IELCAP. The composite model detected 63 of 65 cancers (sensitivity 96.9%) and classified 2,731 of 4,965 non-cancer examinations as negative (specificity 55.0%). Its positive predictive value was 2.7%.

Interpretation

Combining whole-scan and nodule-centered AI yielded high sensitivity across these two cohorts, with moderate specificity. Because this was a retrospective evaluation in existing screening datasets, prospective assessment is needed to establish how the approach performs in routine practice and whether it improves clinical outcomes.

Abstract

Purpose: To evaluate Sybil, a MONAI-based nodule model, and their combination for one-year lung cancer detection in NLST and P-IELCAP. Methods: Baseline LDCT examinations were analyzed; the prespecified OR-stacked model combined Sybil, MONAI nodule detection, and a safety-net rule. Discrimination and operating-point performance were assessed. Results: Among 5,110 examinations, 65 lung cancers were diagnosed within one year. Sybil AUC was 0.93 in both cohorts; MONAI AUCs were 0.90 in NLST and 0.79 in P-IELCAP. The composite model detected 63/65 cancers (sensitivity 96.9%) and classified 2,731/4,965 non-cancer examinations as negative (specificity 55.0%). Conclusion: The composite AI model achieved high sensitivity while maintaining moderate specificity.

Status: Submitted to Radiology: Cardiothoracic Imaging. Manuscript RYCT-26-0087.R3. The full manuscript is not attached.

Download the abstract

Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png

©2026 HeartLung Corporation. All Rights Reserved. U.S. Patent Nos. 12,620,494; 12,599,350; 11,610,686. Licensed U.S. Patent Nos. 9,119,590 and 10,695,022. U.S. Patent Applications Pending: 19/390,544; 19/403,750; 19/643,672; 19/728,738; 19/741,766; 18/652,123; 18/771,542; 19/390,629; 19/417,345; 19/467,802; 19/565,385; 19/682,416; 19/690,066. International PCT Applications: PCT/US2025/058510; PCT/US2025/061047; PCT/US2025/058505; PCT/US2026/013566; PCT/US2026/024304. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoLiver, AutoChamber, AutoLung and other product names and trademarks displayed on this website are protected by applicable intellectual property laws. All rights reserved.

bottom of page